BRPI0509135A - composição farmacêutica de liberação controlada e método para produzir a mesma - Google Patents
composição farmacêutica de liberação controlada e método para produzir a mesmaInfo
- Publication number
- BRPI0509135A BRPI0509135A BRPI0509135-7A BRPI0509135A BRPI0509135A BR PI0509135 A BRPI0509135 A BR PI0509135A BR PI0509135 A BRPI0509135 A BR PI0509135A BR PI0509135 A BRPI0509135 A BR PI0509135A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- controlled release
- release pharmaceutical
- producing
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
COMPOSIçãO FARMACêTICA DE LIBERAçãO CONTROLADA E MéTODO PARA PRODUZIRA MESMA. é um objeto da presente invenção, no caso uma composição farmacêutica de liberação controlada, particularmente uma composição farmacêutica de liberação por pulso, contendo uma substância ativa fisiologicamente instável em ácido, para prover uma composição farmacêutica que tem pequena variação em tempo de latência de dissolução e alta confiabilidade de características de dissolução. A presente invenção descreve uma composição farmacêutica de liberação controlada compreendendo: a) um núcleo que contém uma substância ativa fisiologicamente instável em ácido e um desintegrante; b) um revestimento de controle de liberação que reveste o núcleo, e que contém um polímero insolúvel em água, um polímero entérico e uma cera hidrofóbica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004093506 | 2004-03-26 | ||
PCT/JP2005/005217 WO2005092336A1 (ja) | 2004-03-26 | 2005-03-23 | 溶出制御製剤とその製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0509135A true BRPI0509135A (pt) | 2007-08-28 |
Family
ID=35055974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0509135-7A BRPI0509135A (pt) | 2004-03-26 | 2005-03-23 | composição farmacêutica de liberação controlada e método para produzir a mesma |
Country Status (17)
Country | Link |
---|---|
US (2) | US20080095839A1 (pt) |
EP (1) | EP1728512A1 (pt) |
JP (1) | JPWO2005092336A1 (pt) |
KR (1) | KR100794078B1 (pt) |
CN (1) | CN1938026A (pt) |
AU (1) | AU2005225283B2 (pt) |
BR (1) | BRPI0509135A (pt) |
CA (1) | CA2557791C (pt) |
IL (1) | IL177087A (pt) |
MX (1) | MXPA06010785A (pt) |
MY (1) | MY139427A (pt) |
NO (1) | NO20064874L (pt) |
NZ (1) | NZ549838A (pt) |
RU (1) | RU2337687C2 (pt) |
TW (1) | TW200602085A (pt) |
WO (1) | WO2005092336A1 (pt) |
ZA (1) | ZA200607603B (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050163846A1 (en) * | 2001-11-21 | 2005-07-28 | Eisai Co., Ltd. | Preparation composition containing acid-unstable physiologically active compound, and process for producing same |
MXPA06010785A (es) * | 2004-03-26 | 2007-03-28 | Eisai R&D Man Co Ltd | Composicion farmaceutica de liberacion controlada y metodo para producir la misma. |
CA2570916C (en) | 2004-06-16 | 2013-06-11 | Tap Pharmaceutical Products, Inc. | Pulsed release dosage form of a ppi |
US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
RU2401125C2 (ru) | 2004-12-27 | 2010-10-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Способ стабилизации лекарственного средства против деменции |
US20090148519A1 (en) * | 2005-09-29 | 2009-06-11 | Yasuhiro Zaima | Pulsed-release preparation having improved disintegration properties in vivo |
EP1872778A1 (en) * | 2006-06-29 | 2008-01-02 | LEK Pharmaceuticals D.D. | Stable pharmaceutical composition with rabeprazole sodium |
DE102006035549A1 (de) * | 2006-07-27 | 2008-01-31 | Evonik Röhm Gmbh | Arzneiform mit mindestens zweischichtiger Trennschicht |
WO2008015530A2 (en) * | 2006-08-03 | 2008-02-07 | Aurobindo Pharma Limited | Stable solid oral formulation of pantoprazole |
WO2008062320A2 (en) | 2006-10-06 | 2008-05-29 | Eisai R&D Management Co., Ltd | Extended release formulations of a proton pump inhibitor |
CN101801350A (zh) | 2007-08-13 | 2010-08-11 | 阿巴斯迪特宁医药有限公司 | 抗滥用药物、使用方法和制备方法 |
JP4864024B2 (ja) * | 2008-02-15 | 2012-01-25 | エスエス製薬株式会社 | 時限放出製剤 |
JP2009191034A (ja) * | 2008-02-15 | 2009-08-27 | Ss Pharmaceut Co Ltd | 時限放出製剤 |
JP2009191036A (ja) * | 2008-02-15 | 2009-08-27 | Ss Pharmaceut Co Ltd | 時限放出製剤 |
EP2255794A1 (en) * | 2009-05-29 | 2010-12-01 | H e x a l Aktiengesellschaft | Enteric coating |
JP5503192B2 (ja) * | 2009-06-03 | 2014-05-28 | 大原薬品工業株式会社 | 生理活性物質含有粒子の製造方法 |
CN102470112A (zh) * | 2009-07-30 | 2012-05-23 | 赢创罗姆有限公司 | 包含阴离子聚合物材料和含6-22个碳原子的饱和单羧酸的盐的组合物 |
US8962020B2 (en) * | 2012-07-26 | 2015-02-24 | Glycadia Inc. | Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid |
JP2014122328A (ja) * | 2012-11-22 | 2014-07-03 | Shin Etsu Chem Co Ltd | 押出成形機又は射出成形機洗浄用組成物及び押出成形機又は射出成形機の洗浄方法 |
US20140275038A1 (en) | 2013-03-15 | 2014-09-18 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
CN103976972B (zh) * | 2014-05-26 | 2017-09-12 | 中国药科大学 | 酒石酸唑吡坦口服脉冲控释给药***及其制备方法 |
US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
US20190008787A1 (en) | 2015-07-17 | 2019-01-10 | BE Pharbel Manufacturing | Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form |
EP3117824A1 (en) | 2015-07-17 | 2017-01-18 | BE Pharbel Manufacturing | Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form |
CN105796532B (zh) * | 2016-03-28 | 2018-12-21 | 中国医药集团总公司四川抗菌素工业研究所 | 一种雷贝拉唑钠缓释胶囊及其制备方法 |
MX2021005691A (es) * | 2018-11-19 | 2021-07-07 | Jazz Pharmaceuticals Ireland Ltd | Formulaciones de farmacos resistentes al alcohol. |
KR20210071242A (ko) * | 2019-12-06 | 2021-06-16 | 진양제약주식회사 | 제약 조성물 |
CN113069428B (zh) * | 2021-04-02 | 2023-02-10 | 珠海润都制药股份有限公司 | 一种雷贝拉唑钠肠溶片的制备方法 |
KR102647279B1 (ko) | 2021-04-08 | 2024-03-18 | 대한뉴팜(주) | 라베프라졸의 우수한 방출 특성을 갖는 라베프라졸 나트륨 및 산화마그네슘을 포함하는 제제 및 이의 제조방법 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2336218C3 (de) * | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
FR2471186A1 (fr) * | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
JPS5846019A (ja) * | 1981-09-14 | 1983-03-17 | Kanebo Ltd | 持続性ニフエジピン製剤 |
US4863744A (en) * | 1984-09-17 | 1989-09-05 | Alza Corporation | Intestine drug delivery |
US4892742A (en) * | 1985-11-18 | 1990-01-09 | Hoffmann-La Roche Inc. | Controlled release compositions with zero order release |
JPH0768125B2 (ja) * | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | 酸不安定化合物の内服用製剤 |
DE3822095A1 (de) * | 1988-06-30 | 1990-01-04 | Klinge Co Chem Pharm Fab | Neue arzneimittelformulierung sowie verfahren zu deren herstellung |
US5229131A (en) * | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
KR930006431B1 (ko) * | 1990-10-11 | 1993-07-16 | 재단법인 한국화학연구소 | 약물의 미세캡슐화 방법 |
YU48263B (sh) * | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola |
US5260068A (en) * | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
FR2692146B1 (fr) * | 1992-06-16 | 1995-06-02 | Ethypharm Sa | Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention. |
US5260069A (en) * | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
US6156343A (en) * | 1994-12-27 | 2000-12-05 | Akzo Nobel N.V. | Controlled release preparation |
US5567441A (en) * | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
ES2137862B1 (es) * | 1997-07-31 | 2000-09-16 | Intexim S A | Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion. |
US6296876B1 (en) * | 1997-10-06 | 2001-10-02 | Isa Odidi | Pharmaceutical formulations for acid labile substances |
SE9704870D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
DK1736144T3 (en) * | 1998-05-18 | 2015-12-07 | Takeda Pharmaceutical | Orally disintegrating tablets. |
JP2000128779A (ja) * | 1998-10-20 | 2000-05-09 | Mitsui Chemicals Inc | 薬物放出制御型製剤 |
SE9803772D0 (sv) * | 1998-11-05 | 1998-11-05 | Astra Ab | Pharmaceutical formulation |
US6183766B1 (en) * | 1999-02-12 | 2001-02-06 | The Procter & Gamble Company | Skin sanitizing compositions |
US6174902B1 (en) * | 1999-04-28 | 2001-01-16 | Sepracor Inc. | R-rabeprazole compositions and methods |
JP2001055322A (ja) * | 1999-08-18 | 2001-02-27 | Tanabe Seiyaku Co Ltd | パルス放出型製剤 |
US6369087B1 (en) * | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US7220762B1 (en) * | 1999-10-20 | 2007-05-22 | Eisai R&D Management Co., Ltd. | Methods for stabilizing benzimidazole compounds |
US6627223B2 (en) * | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
US20020045184A1 (en) * | 2000-10-02 | 2002-04-18 | Chih-Ming Chen | Packaging system |
US20050163846A1 (en) * | 2001-11-21 | 2005-07-28 | Eisai Co., Ltd. | Preparation composition containing acid-unstable physiologically active compound, and process for producing same |
UA76256C2 (en) * | 2001-11-21 | 2006-07-17 | Eisai Co Ltd | Composition containing acid-unstable physiologically active compound and process for its preparation |
EP1501484B2 (en) * | 2002-04-29 | 2010-07-07 | EGIS Gyógyszergyár Nyrt | A process for the preparation of tablets from pharmaceutically active substances having unfavourable tabletting properties with a granulating liquid comprising microcrystalline cellulose |
JP2007526319A (ja) * | 2004-03-03 | 2007-09-13 | テバ ファーマシューティカル インダストリーズ リミティド | 酸不安定性薬物を含んでなる安定な医薬組成物 |
MXPA06010785A (es) * | 2004-03-26 | 2007-03-28 | Eisai R&D Man Co Ltd | Composicion farmaceutica de liberacion controlada y metodo para producir la misma. |
US20090148519A1 (en) * | 2005-09-29 | 2009-06-11 | Yasuhiro Zaima | Pulsed-release preparation having improved disintegration properties in vivo |
-
2005
- 2005-03-23 MX MXPA06010785A patent/MXPA06010785A/es active IP Right Grant
- 2005-03-23 CA CA2557791A patent/CA2557791C/en not_active Expired - Fee Related
- 2005-03-23 JP JP2006511471A patent/JPWO2005092336A1/ja active Pending
- 2005-03-23 EP EP05727021A patent/EP1728512A1/en not_active Withdrawn
- 2005-03-23 BR BRPI0509135-7A patent/BRPI0509135A/pt not_active IP Right Cessation
- 2005-03-23 NZ NZ549838A patent/NZ549838A/en unknown
- 2005-03-23 CN CNA2005800098028A patent/CN1938026A/zh active Pending
- 2005-03-23 US US10/594,436 patent/US20080095839A1/en not_active Abandoned
- 2005-03-23 AU AU2005225283A patent/AU2005225283B2/en not_active Ceased
- 2005-03-23 RU RU2006134052/15A patent/RU2337687C2/ru not_active IP Right Cessation
- 2005-03-23 KR KR1020067019778A patent/KR100794078B1/ko not_active IP Right Cessation
- 2005-03-23 WO PCT/JP2005/005217 patent/WO2005092336A1/ja active Application Filing
- 2005-03-23 MY MYPI20051259A patent/MY139427A/en unknown
- 2005-03-24 TW TW094109169A patent/TW200602085A/zh unknown
-
2006
- 2006-07-25 IL IL177087A patent/IL177087A/en not_active IP Right Cessation
- 2006-09-11 ZA ZA200607603A patent/ZA200607603B/en unknown
- 2006-10-06 US US11/543,991 patent/US20120003311A9/en not_active Abandoned
- 2006-10-26 NO NO20064874A patent/NO20064874L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20060134124A (ko) | 2006-12-27 |
IL177087A0 (en) | 2006-12-10 |
JPWO2005092336A1 (ja) | 2008-02-07 |
KR100794078B1 (ko) | 2008-01-10 |
NZ549838A (en) | 2010-04-30 |
AU2005225283B2 (en) | 2008-09-18 |
IL177087A (en) | 2011-11-30 |
CA2557791C (en) | 2011-03-08 |
US20070110806A1 (en) | 2007-05-17 |
NO20064874L (no) | 2006-12-19 |
US20120003311A9 (en) | 2012-01-05 |
CA2557791A1 (en) | 2005-10-06 |
RU2006134052A (ru) | 2008-04-10 |
RU2337687C2 (ru) | 2008-11-10 |
AU2005225283A1 (en) | 2005-10-06 |
EP1728512A1 (en) | 2006-12-06 |
WO2005092336A1 (ja) | 2005-10-06 |
MY139427A (en) | 2009-09-30 |
CN1938026A (zh) | 2007-03-28 |
ZA200607603B (en) | 2007-05-30 |
TW200602085A (en) | 2006-01-16 |
MXPA06010785A (es) | 2007-03-28 |
US20080095839A1 (en) | 2008-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0509135A (pt) | composição farmacêutica de liberação controlada e método para produzir a mesma | |
BRPI0507473A (pt) | cápsula de gelatina mole, uso de pelo menos um ácido graxo polinsaturado Èmega-3, processo para a manufatura de uma cápsula de gelatina mole, uso de gelatina extraìda por um processo de extração, e, método de tratamento ou de profilaxia de uma condição | |
HRP20190660T1 (hr) | FORMULACIJA N-[2,4-bis(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOHINOLIN-3-KARBOKSAMIDA U OBLIKU TABLETE ZA UPOTREBU U TRETMANU CISTIČNE FIBROZE | |
BRPI0414311A (pt) | formas de dosagem de liberação controlada | |
CL2008000219A1 (es) | Composicion farmaceutica de liberacion modificada que comprende a uno o mas ingredientes farmaceuticamente activos, con solubilidad dependiente del ph, un polimero controlador de la liberacion, agentes facilitadores de la gelificacion; procedimiento | |
BR112014029330A2 (pt) | métodos, sistemas e dispositivos para administração de fármacos e oclusão vascular | |
Han et al. | 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin (TCDD) induces hepatic stellate cell (HSC) activation and liver fibrosis in C57BL6 mouse via activating Akt and NF-κB signaling pathways | |
BRPI0417186A (pt) | método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica | |
BRPI0409715A (pt) | pelìculas comestìveis de dissolução rápida contendo um edulcorante | |
UA92030C2 (ru) | Фармацевтические композиции регулированного высвобождения нестабильных в кислой среде лекарственных средств | |
BR112013030727A2 (pt) | dispositivos para inalação de insumos medicinais, válvulas e componentes do mesmo | |
CL2008003699A1 (es) | Nanopartícula que comprende pioglitazona y un polímero biocompatible, preparación farmacéutica que la contiene; stent (endoprótesis vascular) que la porta; y su uso en la profilaxis o tratamiento de enfermedades arterioescleróticas. | |
BRPI0418275A (pt) | formulações em multipartìculas para distribuição oral | |
Arsenijevic et al. | The beneficial role of Filipendula ulmaria extract in prevention of prodepressant effect and cognitive impairment induced by nanoparticles of calcium phosphates in rats | |
Utari et al. | The intrasulcular application effect of bisphosphonate hydrogel toward osteoclast activity and relapse movement | |
PA8853801A1 (es) | Composición de liberación pulsátil de sildenafil y proceso para prepararla | |
BRPI0605893A (pt) | composição farmacêutica, cápsula única, forma unitária de dosagem oral única, processos de produção de uma composição farmacêutica, dos ingredientes ativos cristalinos e recristalizado do ácido suberoilanilida hidroxámico, e de obtenção do ácido suberoilanilida hidroxámico cristalino, e, composição cristalina | |
HRP20130225T1 (hr) | Formulacija s odgođenim otpuštanjem koja sadrži 3-(2-dimetilaminometilcikloheksil) fenol | |
Cheung et al. | Stability and morbidity of Le Fort I osteotomy with bioresorbable fixation: a randomized controlled trial | |
Togni et al. | Histomorphometric analysis of bone tissue repair in rabbits after insertion of titanium screws under different torque | |
Sholts et al. | In utero/lactational and adult exposures to 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) show differential effects on craniofacial development and growth in rats | |
ECSP099251A (es) | Formulaciones farmacéuticas | |
NZ605562A (en) | Deuterated benzylbenzene derivatives and methods of use | |
BR112018074840A2 (pt) | modelos cirúrgicos com marcações radiopacas | |
Sammartino et al. | Local delivery of the hemostatic agent tranexamic acid in chronically anticoagulated patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013. |